Geron publishes IMbark imetelstat myelofibrosis survival presentation

Geron Corporation

Geron Corporation

GERN

0.00
  • Geron published a medical research presentation comparing imetelstat with best available therapy in relapsed or refractory myelofibrosis.
  • Updated analysis showed median overall survival of 30.7 months with imetelstat versus 15.4 months in matched real-world data; hazard ratio 0.512; P=.003.
  • Propensity-weighted analyses were consistent; ATO median overall survival 32.0 months versus 14.9 months; hazard ratio 0.467; P=.0019.
  • Real-world outcomes improved over time; median overall survival 34.2 months for patients diagnosed after 2016 versus 15.4 months before; hazard ratio 0.492; P=.008.
  • Treatment patterns shifted, with shorter time to start ruxolitinib and shorter ruxolitinib duration in patients diagnosed after 2016.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.